For Immediate Release CONTACT: Kyla Clark National Bleeding Disorders Foundation 347-920-0047kclark@bleeding.org NATIONAL BLEEDING DISORDERS FOUNDATION STANDS IN SUPPORT OF WFH’S STATEMENT REGARDING…
Late in 2023 the U.S. Food and Drug Administration (FDA) approved a pair of new therapies that represented a significant scientific breakthrough in gene therapy to treat patients with sickle cell disease (SCD), a rare condition with historically few…
May is Mental Health Awareness Month, and HANDI, in keeping with this theme, is excited to focus on resources that support mental well-being. This edition highlights this important topic from a variety of perspectives and through multiple formats,…
For Immediate Release CONTACT: Kyla Clark National Bleeding Disorders Foundation 347-920-0047kclark@bleeding.org NBDF Celebrates HHS Final Rule Strengthening Protections Against Disability…
Empower Your Journey: Explore the Own Your Path and THRIVE Programs with NBDF's Education Department
Speakers: Brendan Hayes, Heather Hicks, Lena Volland, Ryan Sarshuri Host: Fiona Robinson, Ph.D. Description: Register to join us for a free webinar and learn about a new dynamic NBDF…
The U.S. Food and Drug Administration (FDA) has approved updated prescribing information for ALTUVIIIO™ (Sanofi) to include the full results of the phase 3 XTEND-Kids clinical trial. ALTUVIIIO is a recombinant factor VIII…
Results of a new study published in the Journal of Blood Medicine (JBM), indicate that people with hemophilia A (HA) who have been on a prophylactic treatment regimen have a reduced risk for intracranial hemorrhage (ICH). Often…
For Immediate Release CONTACT: Kyla Clark National Bleeding Disorders Foundation 347-920-0047kclark@bleeding.org NBDF Releases Statement on UK Infected Blood ScandalNBDF Stands…